The Stop TB Partnership released its November 2020 newsletter, summarizing the initiatives and activities carried out during the month, including highlights from the 33rd Stop TB Partnership Board meeting, held virtually on 18-20 November 2020.

Dynamics proprietary Nanowave technology, the first technology to inactivate SARS-CoV-2, the virus that causes COVID-19, has successfully inactivated the deadly Staphylococcus bacteria in fast moving air and inactivation rates have been developed for the pathogens that cause the common cold, staph infection, influenza, and tuberculosis, among others. In November, Dynamics released Nanowave Air™, the first publicly available product to incorporate the Nanowave technology.

Tuberculosis diagnosis based on cellphone camera photos of chest-rays appeared accurate enough to be of use in resource-poor areas, researchers reported at the virtual meeting of the Radiological Society of North America.

New York, Dec. 1 2020 — The global COVID-19 pandemic has strained health care systems around the world. In the developing world, tuberculosis (TB), which shares several symptoms with COVID-19, is often the first sign that a person has HIV. This World AIDS Day, the Forum of International Respiratory Societies (FIRS), is calling on governments, health advocates and non-government organisations to strengthen their response to AIDS and tuberculosis, and to ensure that TB services are maintained throughout their response to COVID-19.

On the occasion of World AIDS Day, 1 December, the World Health Organization Global TB Program delivered a special message highlighting the need to expand and strengthen integration of services within the primary healthcare platform, optimizing differentiated service delivery, community engagement and the use of digital technologies to reach those most at risk of TB and HIV with screening, prevention, diagnosis and treatment.

The International Union Against Tuberculosis and Lung Disease (The Union) released its November 2020 newsletter, summarizing the initiatives and activities carried out during the month.

RESIST-TB released its November 2020 newsletter with the latest research publications on drug-resistant TB.

New Delhi: A Government of India drugs advisory committee has approved the use of Johnson & Johnson’s (J&J) bedaquiline – used to treat tuberculosis (TB) – for minor patients in the country without conducting any local clinical trials first.

Over 300 representatives from countries, partners and civil society came together virtually at the Global Working Group Meeting on Public-Private Mix (PPM) on TB prevention and care on 23 and 25 November 2020. The Meeting was convened by the World Health Organization and the Stop TB Partnership with support from the U.S. Agency for International Development (USAID) and the Global Fund.

The Communities Delegation to the Unitaid Board represents people living with and affected by HIV, TB and malaria and those co-infected with HIV and HCV, at Unitaid Board and Committee level. The Communities Delegation is currently inviting applications for membership from people living with HIV, and affected by TB or malaria for the period 2021-2024. The Delegation would like to recruit additional members from under-represented regions and disease areas as well as members from the Long COVID-19 community who are interested to follow the work of the Unitaid-supported Access to COVID-19 Tools Accelerator.